This project aims at assessing the power of a new technology based on mass spectrometry (LiP-MS) to detect aberrant protein structures as a novel type of disease biomarkers. LiP-MS generates a novel type of molecular data that comprehensively and quantitatively describe physiological and pathological states of an organism. To showcase the potential of the technology, the project focuses on the use of LiP-MS for the identification of novel PD biomarkers for early disease detection and predictors of cognitive decline.